Flex Pharma Stock Price, News & Analysis (NASDAQ:FLKS)

$4.18 0.12 (2.96 %)
(As of 11/17/2017 02:17 PM ET)
Previous Close$4.18
Today's Range$3.78 - $4.20
52-Week Range$2.68 - $7.10
Volume37,800 shs
Average Volume46,612 shs
Market Capitalization$75.12 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Flex Pharma (NASDAQ:FLKS)

Flex Pharma logoFlex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:FLKS
  • CUSIP: N/A
  • Web: www.flex-pharma.com
Debt:
  • Current Ratio: 8.16%
  • Quick Ratio: 8.05%
Sales & Book Value:
  • Annual Sales: $1.01 million
  • Price / Sales: 74.37
  • Book Value: $2.01 per share
  • Price / Book: 2.08
Profitability:
  • Trailing EPS: ($2.02)
  • Net Income: ($39,490,000.00)
  • Net Margins: -2,655.19%
  • Return on Equity: -71.39%
  • Return on Assets: -65.49%
Misc:
  • Employees: 31
  • Outstanding Shares: 17,970,000
 

Frequently Asked Questions for Flex Pharma (NASDAQ:FLKS)

What is Flex Pharma's stock symbol?

Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."

How were Flex Pharma's earnings last quarter?

Flex Pharma, Inc. (NASDAQ:FLKS) issued its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.60) by $0.06. The biotechnology company earned $0.41 million during the quarter, compared to the consensus estimate of $0.47 million. Flex Pharma had a negative return on equity of 71.39% and a negative net margin of 2,655.19%. View Flex Pharma's Earnings History.

Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?

4 brokers have issued 1-year target prices for Flex Pharma's stock. Their forecasts range from $8.00 to $14.00. On average, they expect Flex Pharma's share price to reach $11.00 in the next twelve months. View Analyst Ratings for Flex Pharma.

What are Wall Street analysts saying about Flex Pharma stock?

Here are some recent quotes from research analysts about Flex Pharma stock:

  • 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (11/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "Exploratory Phase II study of FLX-787 in ALS has produced statistically significant results in decreased pain intensity and stiffness (p<0.05) in a small population of 8 patients."" (11/6/2017)

Who are some of Flex Pharma's key competitors?

Who are Flex Pharma's key executives?

Flex Pharma's management team includes the folowing people:

  • Christoph H. Westphal M.D. Ph.D., Chairman of the Board (Age 48)
  • William K. McVicar Ph.D., President, Chief Executive Officer, Director (Age 59)
  • John McCabe, Chief Financial Officer, Treasurer (Age 45)
  • Kathie Lindemann, Chief Operating Officer (Age 54)
  • Jennifer Cermak Ph.D., Vice President - Research & Development (Age 42)
  • Robert Hadfield Ph.D., General Counsel, Secretary (Age 37)
  • Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications (Age 49)
  • Thomas C. Wessel M.D. Ph.D., Chief Medical Officer (Age 60)
  • Jeffrey D. Capello, Director (Age 50)
  • Roderick Mackinnon M.D, Director (Age 59)

When did Flex Pharma IPO?

(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Who owns Flex Pharma stock?

Flex Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ameriprise Financial Inc. (4.01%), C WorldWide Group Holding A S (1.45%) and Sphera Funds Management LTD. (0.79%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Institutional Ownership Trends for Flex Pharma.

Who sold Flex Pharma stock? Who is selling Flex Pharma stock?

Flex Pharma's stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S. View Insider Buying and Selling for Flex Pharma.

Who bought Flex Pharma stock? Who is buying Flex Pharma stock?

Flex Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Ameriprise Financial Inc.. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Insider Buying and Selling for Flex Pharma.

How do I buy Flex Pharma stock?

Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flex Pharma's stock price today?

One share of Flex Pharma stock can currently be purchased for approximately $4.18.

How big of a company is Flex Pharma?

Flex Pharma has a market capitalization of $75.12 million and generates $1.01 million in revenue each year. The biotechnology company earns ($39,490,000.00) in net income (profit) each year or ($2.02) on an earnings per share basis. Flex Pharma employs 31 workers across the globe.

How can I contact Flex Pharma?

Flex Pharma's mailing address is 800 Boylston St Fl 24, BOSTON, MA 02199-8119, United States. The biotechnology company can be reached via phone at +1-617-8741821 or via email at [email protected]


MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  327
MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Flex Pharma (NASDAQ:FLKS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $11.00 (163.16% upside)

Consensus Price Target History for Flex Pharma (NASDAQ:FLKS)

Price Target History for Flex Pharma (NASDAQ:FLKS)

Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017Cantor FitzgeraldReiterated RatingHold$10.00N/AView Rating Details
9/7/2017Roth CapitalInitiated CoverageBuy$14.00LowView Rating Details
5/4/2017Jefferies Group LLCLower Price TargetBuy$9.00 -> $8.00HighView Rating Details
3/8/2017Piper Jaffray CompaniesSet Price TargetBuy$12.00LowView Rating Details
11/3/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/15/2016HC WainwrightReiterated RatingBuy$40.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Flex Pharma (NASDAQ:FLKS)

Earnings by Quarter for Flex Pharma (NASDAQ:FLKS)

Earnings History by Quarter for Flex Pharma (NASDAQ FLKS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.60)($0.54)$0.47 million$0.41 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.63)($0.51)$0.46 million$0.34 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.62)($0.49)$0.38 million$0.24 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.84)($0.48)$0.09 million$0.30 millionViewListenView Earnings Details
11/2/2016Q316($0.72)($0.65)$0.15 million$0.60 millionViewListenView Earnings Details
8/3/2016Q216($0.67)($0.71)$0.01 million$0.11 millionViewListenView Earnings Details
5/4/2016Q1($0.56)($0.61)ViewListenView Earnings Details
3/8/2016Q415($0.56)($0.51)ViewListenView Earnings Details
11/4/2015Q315($0.44)($0.53)ViewListenView Earnings Details
8/5/2015Q215($0.37)($0.47)ViewListenView Earnings Details
5/6/2015Q1($0.32)($0.59)ViewListenView Earnings Details
3/17/2015Q4($0.12)($1.82)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
2017 EPS Consensus Estimate: ($1.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.46)($0.46)($0.46)
Q3 20171($0.56)($0.56)($0.56)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Flex Pharma (NASDAQ FLKS)

Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 28.07%
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)

Insider Trades by Quarter for Flex Pharma (NASDAQ FLKS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2016Christoph H WestphalInsiderBuy7,000$7.31$51,170.00View SEC Filing  
11/7/2016Christoph H WestphalInsiderBuy8,870$5.70$50,559.00View SEC Filing  
11/7/2016John P MccabeVPBuy1,650$6.01$9,916.50View SEC Filing  
6/23/2016Christoph H WestphalCEOBuy2,700$11.28$30,456.00View SEC Filing  
6/22/2016Christoph H WestphalCEOBuy5,700$11.05$62,985.00View SEC Filing  
6/21/2016Christoph H WestphalCEOBuy2,800$11.07$30,996.00View SEC Filing  
6/20/2016Christoph H WestphalCEOBuy6,000$11.18$67,080.00View SEC Filing  
6/16/2016Christoph H WestphalCEOBuy5,800$11.17$64,786.00View SEC Filing  
6/14/2016Christoph H WestphalCEOBuy5,900$11.54$68,086.00View SEC Filing  
6/10/2016Christoph H WestphalCEOBuy6,000$11.94$71,640.00View SEC Filing  
6/8/2016Christoph H WestphalCEOBuy5,900$12.25$72,275.00View SEC Filing  
6/6/2016Christoph H WestphalCEOBuy6,000$12.56$75,360.00View SEC Filing  
6/2/2016Christoph H WestphalCEOBuy10,000$12.99$129,900.00View SEC Filing  
5/31/2016Christoph H WestphalCEOBuy22,300$12.68$282,764.00View SEC Filing  
5/26/2016Christoph H WestphalCEOBuy28,600$12.84$367,224.00View SEC Filing  
5/24/2016Christoph H WestphalCEOBuy30,334$12.42$376,748.28View SEC Filing  
5/20/2016Christoph H WestphalCEOBuy7,914$11.06$87,528.84View SEC Filing  
5/18/2016Christoph H WestphalCEOBuy33,400$11.10$370,740.00View SEC Filing  
5/16/2016Christoph H WestphalCEOBuy15,469$10.25$158,557.25View SEC Filing  
5/12/2016Christoph H WestphalCEOBuy30,217$10.12$305,796.04View SEC Filing  
5/10/2016Christoph H WestphalCEOBuy30,109$9.94$299,283.46View SEC Filing  
3/24/2016Christoph H WestphalCEOBuy49,563$11.06$548,166.78View SEC Filing  
3/22/2016Christoph H WestphalCEOBuy23,951$11.78$282,142.78View SEC Filing  
3/21/2016Christoph H WestphalCEOBuy48,058$11.74$564,200.92View SEC Filing  
3/18/2016Christoph H WestphalCEOBuy37,574$11.00$413,314.00View SEC Filing  
3/16/2016Christoph H WestphalCEOBuy38,379$10.23$392,617.17View SEC Filing  
3/15/2016Michelle StacyDirectorBuy2,585$9.63$24,893.55View SEC Filing  
3/14/2016Thomas WesselInsiderBuy20,000$7.94$158,800.00View SEC Filing  
3/11/2016Christoph H WestphalCEOBuy89,680$7.00$627,760.00View SEC Filing  
3/11/2016Roderick MackinnonDirectorBuy10,000$7.03$70,300.00View SEC Filing  
12/14/2015Christoph H WestphalCEOBuy927$12.01$11,133.27View SEC Filing  
12/7/2015Christoph H WestphalCEOBuy907$12.02$10,902.14View SEC Filing  
11/19/2015Marc D KozinDirectorBuy4,500$11.38$51,210.00View SEC Filing  
11/16/2015Christoph H WestphalCEOBuy1,001$10.78$10,790.78View SEC Filing  
11/9/2015Christoph H WestphalCEOBuy1,000$11.03$11,030.00View SEC Filing  
10/26/2015Christoph H WestphalCEOBuy1,043$10.55$11,003.65View SEC Filing  
10/19/2015Christoph H WestphalCEOBuy1,018$10.61$10,800.98View SEC Filing  
9/28/2015Christoph H WestphalCEOBuy924$11.18$10,330.32View SEC Filing  
3/30/2015Christoph H WestphalCEOBuy272$20.52$5,581.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Flex Pharma (NASDAQ:FLKS)

Latest Headlines for Flex Pharma (NASDAQ FLKS)

Source:
DateHeadline
Analyzing Flex Pharma (FLKS) & Urogen Pharma (URGN)Analyzing Flex Pharma (FLKS) & Urogen Pharma (URGN)
www.americanbankingnews.com - November 17 at 2:12 PM
Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $380,000.00Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $380,000.00
www.americanbankingnews.com - November 11 at 6:38 AM
Jefferies Group Analysts Boost Earnings Estimates for Flex Pharma, Inc. (FLKS)Jefferies Group Analysts Boost Earnings Estimates for Flex Pharma, Inc. (FLKS)
www.americanbankingnews.com - November 10 at 7:40 AM
 Analysts Anticipate Flex Pharma, Inc. (FLKS) to Post -$0.86 Earnings Per Share Analysts Anticipate Flex Pharma, Inc. (FLKS) to Post -$0.86 Earnings Per Share
www.americanbankingnews.com - November 9 at 3:54 PM
Flex Pharma, Inc. (FLKS) Posts  Earnings Results, Beats Expectations By $0.06 EPSFlex Pharma, Inc. (FLKS) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - November 7 at 10:08 AM
Flex Pharma, Inc. to Host Earnings CallFlex Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALSFlex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in ALS
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma Reports Third Quarter 2017 Financial ResultsFlex Pharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 6 at 10:38 PM
Flex Pharma reports 3Q lossFlex Pharma reports 3Q loss
finance.yahoo.com - November 6 at 10:38 PM
Edited Transcript of FLKS earnings conference call or presentation 6-Nov-17 1:45pm GMTEdited Transcript of FLKS earnings conference call or presentation 6-Nov-17 1:45pm GMT
finance.yahoo.com - November 6 at 10:38 PM
Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma, Inc. (FLKS)Cantor Fitzgerald Reaffirms Hold Rating for Flex Pharma, Inc. (FLKS)
www.americanbankingnews.com - November 6 at 4:18 PM
Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
finance.yahoo.com - November 2 at 8:00 PM
Flex Pharma Names Dr. Roger Tung to Its Board of DirectorsFlex Pharma Names Dr. Roger Tung to Its Board of Directors
finance.yahoo.com - October 31 at 7:56 PM
Should You Buy Flex Pharma Inc (FLKS) Now?Should You Buy Flex Pharma Inc (FLKS) Now?
finance.yahoo.com - October 31 at 7:56 PM
Flex Pharma, Inc. (FLKS) Scheduled to Post Earnings on TuesdayFlex Pharma, Inc. (FLKS) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 24 at 5:46 AM
$470,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter$470,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - October 22 at 5:04 AM
Flex Pharma (FLKS) and Kitov Pharmaceuticals Holdings (KTOV) Head to Head ContrastFlex Pharma (FLKS) and Kitov Pharmaceuticals Holdings (KTOV) Head to Head Contrast
www.americanbankingnews.com - October 21 at 4:24 AM
Flex Pharma, Inc. (FLKS) Expected to Post Earnings of -$0.62 Per ShareFlex Pharma, Inc. (FLKS) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - October 20 at 8:28 PM
Flex Pharma (FLKS) Initiates CMT Phase 2 Trial with FLX-787 in U.S.Flex Pharma (FLKS) Initiates CMT Phase 2 Trial with FLX-787 in U.S.
www.streetinsider.com - October 17 at 5:07 AM
Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in USFlex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
finance.yahoo.com - October 16 at 7:04 PM
Flex Pharma, Inc. (FLKS) Given Average Rating of "Buy" by AnalystsFlex Pharma, Inc. (FLKS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 11:06 AM
 Analysts Expect Flex Pharma, Inc. (FLKS) Will Announce Quarterly Sales of $470,000.00 Analysts Expect Flex Pharma, Inc. (FLKS) Will Announce Quarterly Sales of $470,000.00
www.americanbankingnews.com - October 4 at 5:40 PM
Head to Head Comparison: Flex Pharma (FLKS) vs. Axovant Sciences (AXON)Head to Head Comparison: Flex Pharma (FLKS) vs. Axovant Sciences (AXON)
www.americanbankingnews.com - October 1 at 6:24 AM
Flex Pharma, Inc. (FLKS) Receives Hold Rating from Cantor FitzgeraldFlex Pharma, Inc. (FLKS) Receives Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 9:14 PM
Flex Pharma, Inc. (FLKS) Receives Consensus Rating of "Buy" from AnalystsFlex Pharma, Inc. (FLKS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 11:02 AM
Flex Pharma, Inc. (FLKS) Coverage Initiated at Roth CapitalFlex Pharma, Inc. (FLKS) Coverage Initiated at Roth Capital
www.americanbankingnews.com - September 7 at 8:58 PM
Flex Pharma Presenting at Upcoming Investor Conferences in September 2017Flex Pharma Presenting at Upcoming Investor Conferences in September 2017
finance.yahoo.com - September 6 at 6:35 PM
ETFs with exposure to Flex Pharma, Inc. : September 1, 2017ETFs with exposure to Flex Pharma, Inc. : September 1, 2017
finance.yahoo.com - September 2 at 12:00 AM
$500,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter$500,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - August 27 at 4:46 AM
Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 8:06 PM
Cantor Fitzgerald Weighs in on Flex Pharma, Inc.s FY2017 Earnings (NASDAQ:FLKS)Cantor Fitzgerald Weighs in on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 10 at 9:10 AM
Flex Pharma, Inc. (NASDAQ:FLKS) Expected to Post Quarterly Sales of $500,000.00Flex Pharma, Inc. (NASDAQ:FLKS) Expected to Post Quarterly Sales of $500,000.00
www.americanbankingnews.com - August 9 at 7:24 AM
Jefferies Group Comments on Flex Pharma, Inc.s FY2017 Earnings (NASDAQ:FLKS)Jefferies Group Comments on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 7 at 7:46 AM
Edited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMTEdited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT
finance.yahoo.com - August 3 at 4:01 PM
Flex Pharma, Inc. (FLKS) Posts Quarterly  Earnings Results, Beats Estimates By $0.12 EPSFlex Pharma, Inc. (FLKS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - August 3 at 2:52 PM
Investor Network: Flex Pharma, Inc. to Host Earnings CallInvestor Network: Flex Pharma, Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 7:37 PM
Flex Pharma Reports Second Quarter 2017 Financial ResultsFlex Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 7:37 PM
Flex Pharma reports 2Q lossFlex Pharma reports 2Q loss
finance.yahoo.com - August 2 at 7:37 PM
Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in USFlex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
finance.yahoo.com - August 1 at 7:17 PM
Flex Pharma Names William McVicar President and Chief Executive OfficerFlex Pharma Names William McVicar President and Chief Executive Officer
finance.yahoo.com - July 31 at 6:25 PM
Flex Pharma, Inc. (NASDAQ:FLKS) Receives Average Recommendation of "Buy" from AnalystsFlex Pharma, Inc. (NASDAQ:FLKS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM
Corporate News Blog - FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALSCorporate News Blog - FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 27 at 7:14 PM
Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
finance.yahoo.com - July 27 at 12:17 AM
FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALSFDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 25 at 6:57 PM
$460,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter$460,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - July 20 at 1:46 PM
Flex Pharma, Inc. (NASDAQ:FLKS) Short Interest Down 56.7% in JuneFlex Pharma, Inc. (NASDAQ:FLKS) Short Interest Down 56.7% in June
www.americanbankingnews.com - July 16 at 7:08 AM
Flex Pharma, Inc. (NASDAQ:FLKS) Given Average Recommendation of "Buy" by BrokeragesFlex Pharma, Inc. (NASDAQ:FLKS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 11:24 AM
HOTSHOT Partners With IRONMAN To Help Athletes Prevent Muscle CrampingHOTSHOT Partners With IRONMAN To Help Athletes Prevent Muscle Cramping
www.bizjournals.com - June 29 at 4:21 AM
Flex Pharma (FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth by Inherited Neuropathies ConsortiumFlex Pharma (FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth by Inherited Neuropathies Consortium
www.streetinsider.com - June 2 at 6:33 PM
Flex Pharma Announce Presentation of Human Efficacy Data on FLX-787 at American Academy of Neurology Annual Meeting on 4/27Flex Pharma Announce Presentation of Human Efficacy Data on FLX-787 at American Academy of Neurology Annual Meeting on 4/27
www.streetinsider.com - April 19 at 5:07 PM

Social Media

Financials

Chart

Flex Pharma (NASDAQ FLKS) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.